<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820714</url>
  </required_header>
  <id_info>
    <org_study_id>BLI801-204</org_study_id>
    <nct_id>NCT02820714</nct_id>
  </id_info>
  <brief_title>A Pilot Study of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation</brief_title>
  <official_title>A Pilot Study of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate BLI801 laxative in adults experiencing&#xD;
      non-idiopathic constipation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of subjects with treatment response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Greater than or equal to 3 spontaneous bowel movements per week for 2 out of 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of subjects with treatment emergent adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>BLI801 Laxative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLI801 oral laxative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI801 Laxative</intervention_name>
    <description>BLI801 Laxative</description>
    <arm_group_label>BLI801 Laxative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects at least 18 years of age&#xD;
&#xD;
          2. Taking medication known to cause constipation. This medication should remain stable&#xD;
             throughout the study.&#xD;
&#xD;
          3. Constipated, defined by the following criteria: Fewer than 3 spontaneous defecations&#xD;
             per week and at least one of the following symptoms for the previous 4 weeks:&#xD;
&#xD;
               -  Straining during &gt; 25% of defecations&#xD;
&#xD;
               -  Lumpy or hard stools in &gt; 25% of defecations&#xD;
&#xD;
               -  Sensation of incomplete evacuation for &gt; 25% of defecations&#xD;
&#xD;
             Onset of constipation must coincide with the instruction of treatment with a&#xD;
             constipating medication&#xD;
&#xD;
          4. Otherwise in good health, as determined by physical exam and medical history&#xD;
&#xD;
          5. If female, and of child-bearing potential, is using an acceptable form of birth&#xD;
             control&#xD;
&#xD;
          6. Negative urine pregnancy test at screening (visit 1), if applicable&#xD;
&#xD;
          7. In the Investigator's judgment, subject is mentally competent to provide informed&#xD;
             consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects whose constipation diagnosis and symptoms predate the initiation of treatment&#xD;
             with the constipating medication.&#xD;
&#xD;
          2. Subjects with known or suspected ileus, gastrointestinal obstruction, gastric&#xD;
             retention, bowel perforation, toxic colitis, toxic megacolon&#xD;
&#xD;
          3. Subjects who have had major surgery 30 days before Visit 1; appendectomy or&#xD;
             cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery&#xD;
             6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI&#xD;
             tract at any time before Visit 1&#xD;
&#xD;
          4. Medical conditions associated with diarrhea, intermittent loose stools, or&#xD;
             constipation, which could confound the interpretation of the results, eg, fecal&#xD;
             incontinence or irritable bowel syndrome. Subjects with irritable bowel syndrome (IBS)&#xD;
             that has been previously diagnosed by a physician prior to initiation of the&#xD;
             constipating therapy and that meets the following criteria, are excluded:&#xD;
&#xD;
               1. Absence of a structural or biochemical explanation for the abdominal pain symptom&#xD;
&#xD;
               2. At least 12 weeks during a period of 12 months, of abdominal discomfort or pain&#xD;
                  with at least 2 of the following 3 features:&#xD;
&#xD;
                    -  Relieved with defecation, and/or&#xD;
&#xD;
                    -  Onset associated with a change in frequency of stool, and/or&#xD;
&#xD;
                    -  Onset associated with a change in form of stool.&#xD;
&#xD;
          5. Subjects taking other prohibited concomitant medications.&#xD;
&#xD;
          6. Subjects who are pregnant or nursing, or intend to become pregnant during the study&#xD;
&#xD;
          7. Subjects of childbearing potential who refuse a pregnancy test&#xD;
&#xD;
          8. Subjects who are allergic to any BLI801 component&#xD;
&#xD;
          9. Active substance or alcohol use that, in the opinion of the investigator, could&#xD;
             compromise patient's ability to comply with the study instructions.&#xD;
&#xD;
         10. Subjects who have participated in an investigational clinical, surgical, drug, or&#xD;
             device study within the past 30 days&#xD;
&#xD;
         11. Subjects who, in the opinion of the Investigator, should not be included in the study&#xD;
             for any reason, including inability to follow study procedures.&#xD;
&#xD;
         12. Subjects who withdraw consent at any time prior to completion of Visit 1 procedures&#xD;
&#xD;
         13. Subjects who have had a colonoscopy within 2 weeks of Visit 1 or are scheduled to have&#xD;
             a colonoscopy during their participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Braintree Research Site 1</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Braintree Research Site 3</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Braintree Research Site 2</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <disposition_first_submitted>September 26, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>September 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 28, 2018</disposition_first_posted>
  <last_update_submitted>September 26, 2018</last_update_submitted>
  <last_update_submitted_qc>September 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laxatives</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

